NEW YORK, Jan. 23 - Galapagos Genomics and Exelixis have penned an agreement under which Exelixis will use Galapagos' adenoviral technology to analyze gene function in cell-based assays.
Galapagos, a functional genomics company based in Belgium, will reconstruct recombinant adenoviruses that include genes selected by Exelixis. Researchers at Exelixis will then introduce the vectors into a range of cell types in order to evaluate protein function of the selected genes in disease-relevant pathways.
Financial details of the deal were not disclosed.
Galapagos' technology can be used to link genes with a range of phenotypic characteristics like morphology, motility, proliferation, differentiation and signal transduction.